New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir

ConclusionsIn patients without NS5A L31 or Y93 RASs, the presence of NS5A Q24, L28, and/or R30 RASs and concomitant NS5A F37 and Q54 RASs at the baseline was associated with failure of DCV and ASV combination therapy. The coexistence of baseline RASs other than NS5A L31 and Y93 may affect the therapeutic effectiveness of DCV and ASV combination therapy.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research